{"symbol":"BMY","fiscalQuarter":"Q4-2015","reportDate":"2016-01-28","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q4-2015","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 0.89%","keyNumbers":[{"metric":"EPS","actual":"$0.38","expected":"N/A","surprise":"+36.20%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key therapeutic areas.","They noted ongoing investments in research and development.","The team expressed confidence in future product pipeline."],"summary":"Overall, management conveyed a positive outlook on their product pipeline and market position. However, they did not provide specific guidance for the upcoming quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report shows a strong EPS performance, exceeding expectations significantly. However, the stock reacted negatively, declining by 0.89%, possibly due to the lack of revenue details and forward guidance. Investors may be cautious as they await more information on future performance and product developments.","metaDescription":"Bristol Myers Squibb (BMY) Q4 2015 earnings: EPS beat by 36.2%. Stock down 0.89%. Full breakdown."}}